Whole genome sequencing analysis demonstrates therapy‐induced echinocandin resistance in Candida auris isolates

Candida auris is an emerging, multidrug‐resistant yeast, causing outbreaks in healthcare facilities. Echinocandins are the antifungal drugs of choice to treat candidiasis, as they cause few side effects and resistance is rarely found. Previously, immunocompromised patients from Kuwait with C . auris colonisation or infection were treated with echinocandins, and within days to months, resistance was reported in urine isolates. To determine whether the development of echinocandin resistance was due to independent introductions of resistant strains or resulted from intra‐patient resistance development, whole genome sequencing (WGS) single‐nucleotide polymorphism (SNP) analysis was performed on susceptible ( n = 26) and echinocandin‐resistant ( n = 6) isolates from seven patients. WGS SNP analysis identified three distinct clusters differing 17–127 SNPs from two patients, and the remaining isolates from five patients, respectively. Sequential isolates within patients had a maximum of 11 SNP differences over a time period of 1–10 months. The majority of isolates with reduced susceptibility displayed unique FKS1 substitutions including a novel FKS1 M690V substitution, and nearly all were genetically related, ranging from only three to six SNP differences compared to susceptible isolates from the same patient. Resistant isolates from three patients shared the common FKS1 S639F substitution; however, WGS analysis did not suggest a common source. These findings strongly indicate that echinocandin resistance is induced during antifungal treatment. Future studies should determine whether such echinocandin‐resistant strains are capable of long‐term colonisation, cause subsequent breakthrough candidiasis, have a propensity to cross‐infect other patients, or remain viable for longer time periods in the hospital environment.